Abbott Laboratories Q2 Earnings: Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth
Abbott Laboratories Q2 Earnings: Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth
On Thursday, Abbott Laboratories (NYSE:ABT) reported second-quarter sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion.
週四，雅培實驗室(NYSE:ABT)報告了2024年第二季度銷售額爲103.8億美元，增長4%，幾乎符合預期的103.7億美元。
Organic sales growth for the underlying base business was 9.3%, led by double-digit growth in Medical Devices.
基礎業務的有機銷售增長率爲9.3%，其中醫療器械業務的銷售增長率在兩位數以上。
Abbott's adjusted diluted earnings per share was $1.14, beating the analyst estimates of $1.10.
雅培的調整後稀釋每股收益爲1.14美元，超出分析師的預期1.10美元。
Medical Devices sales increased 10.2% to $4.73 billion and 12.1% organically in the second quarter, including double-digit organic growth in the U.S. and internationally. Sales growth was led by double-digit growth in Diabetes Care, Electrophysiology, and Structural Heart.
第二季度醫療器械銷售額爲47.3億美元，增長10.2%，有機增長12.1%，包括美國和國際雙位數有機增長。增長主要來自糖尿病護理、心臟電生理學和結構性心臟的雙位數增長。
Year-over-year declines in COVID-19 testing-related sales negatively impacted diagnostics sales growth in the second quarter. Sales reached $2.19 billion, down 5.3% (-1.5% organically).
第二季度COVID-19測試相關銷售同比下降，對診斷業務銷售增長產生了負面影響。銷售額達到21.9億美元，同比下降5.3%（有機下降1.5%）。
Worldwide COVID-19 testing sales were $102 million in the second quarter of 2024 compared to $263 million a year ago.
2024年第二季度全球COVID-19測試銷售額爲10200萬美元，相比之下去年同期爲26300萬美元。
Nutrition sales increased 3.5% to $2.15 billion (+7.5% organically).
營養品銷售額增長了3.5%至21.5億美元（有機增長7.5%）。
In June, Abbott announced FDA approval for two new over-the-counter continuous glucose monitoring systems: Lingo and Libre Rio. These systems are based on Abbott's FreeStyle Libre continuous glucose monitoring technology.
6月，雅培宣佈FDA批准了兩個新的非處方連續血糖監測系統：Lingo和Libre Rio。這些系統基於雅培的FreeStyle Libre連續血糖監測技術。
During the first half of 2024, Abbott announced ten new growth opportunities from the company's pipeline.
2024年上半年，雅培宣佈了來自公司管線的10個新的增長機會。
Guidance: Abbott projects full-year 2024 GAAP EPS of $3.30-$3.40 versus prior guidance of $3.25-$3.40, primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses.
展望：雅培預計2024年全年GAAP每股收益爲3.30-3.40美元，比先前的指引3.25-3.40美元略高，主要與無形資產攤銷、重組和成本削減計劃以及其他淨開支有關。
The company forecasts adjusted EPS of $4.61-$4.71 versus the prior guidance of $4.55-$4.70 and consensus of $4.63.
該公司預計調整後每股收益爲4.61-4.71美元，而先前的指引爲4.55-4.70美元，預期爲4.63美元。
Price Action: At the last check on Thursday, ABT shares were down 2.52% at $102.04.
股價表現：週四最後一次查看時，雅培(ABT)的股價下跌2.52%，至102.04美元。
- Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits.
- Similac奶粉製造商Abbott和Reckitt面臨數百起嬰兒配方奶粉訴訟。
Photo via Shutterstock
圖片來自shutterstock。